2017 Q3 Form 10-Q Financial Statement
#000119312517252800 Filed on August 09, 2017
Income Statement
| Concept | 2017 Q3 | 2017 Q2 | 2016 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.600M | $1.730M | $2.310M |
| YoY Change | 12.68% | -25.11% | -0.43% |
| % of Gross Profit | |||
| Research & Development | $2.705M | $2.452M | $2.509M |
| YoY Change | 8.46% | -2.28% | -2.66% |
| % of Gross Profit | |||
| Depreciation & Amortization | $12.84K | $12.96K | $8.762K |
| YoY Change | 35.4% | 47.88% | -2.37% |
| % of Gross Profit | |||
| Operating Expenses | $4.307M | $4.181M | $4.814M |
| YoY Change | 10.03% | -13.15% | -1.69% |
| Operating Profit | -$4.307M | -$4.181M | -$4.814M |
| YoY Change | 10.03% | -13.15% | -1.69% |
| Interest Expense | $0.00 | $210.0K | $150.0K |
| YoY Change | -100.0% | 40.0% | -54.55% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $129.1K | $91.04K | $92.76K |
| YoY Change | 92.68% | -1.85% | 1804.23% |
| Pretax Income | -$4.178M | -$3.880M | -$4.569M |
| YoY Change | 5.66% | -15.08% | 0.23% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$4.178M | -$3.880M | -$4.569M |
| YoY Change | 5.66% | -15.08% | 0.23% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$49.29K | -$46.24K | -$55.15K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 84.55M shares | 83.79M shares | 82.87M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q3 | 2017 Q2 | 2016 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $33.90M | $35.10M | $48.00M |
| YoY Change | -24.16% | -26.88% | -28.78% |
| Cash & Equivalents | $7.329M | $8.584M | $18.72M |
| Short-Term Investments | $26.60M | $26.50M | $29.30M |
| Other Short-Term Assets | $600.0K | $600.0K | $600.0K |
| YoY Change | 100.0% | 0.0% | -25.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $34.42M | $35.75M | $48.67M |
| YoY Change | -23.61% | -26.55% | -28.7% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $205.5K | $218.3K | $258.5K |
| YoY Change | -17.5% | -15.56% | 308.44% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Total Long-Term Assets | $214.3K | $227.2K | $267.4K |
| YoY Change | -16.9% | -15.04% | 270.46% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $34.42M | $35.75M | $48.67M |
| Total Long-Term Assets | $214.3K | $227.2K | $267.4K |
| Total Assets | $34.63M | $35.98M | $48.94M |
| YoY Change | -23.57% | -26.48% | -28.38% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.082M | $692.3K | $707.3K |
| YoY Change | 2.49% | -2.11% | -46.27% |
| Accrued Expenses | $1.656M | $1.148M | $1.598M |
| YoY Change | 76.12% | -28.16% | 33.18% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.738M | $1.840M | $2.305M |
| YoY Change | 37.18% | -20.17% | -9.7% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $200.0K | $200.0K | $300.0K |
| YoY Change | -50.0% | -33.33% | -90.0% |
| Total Long-Term Liabilities | $200.0K | $200.0K | $300.0K |
| YoY Change | -50.0% | -33.33% | -90.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.738M | $1.840M | $2.305M |
| Total Long-Term Liabilities | $200.0K | $200.0K | $300.0K |
| Total Liabilities | $2.902M | $2.011M | $2.616M |
| YoY Change | 20.43% | -23.12% | -52.83% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$121.2M | -$117.0M | -$100.0M |
| YoY Change | 16.53% | 16.96% | 25.33% |
| Common Stock | $85.24K | $84.56K | $82.87K |
| YoY Change | 2.85% | 2.03% | 0.94% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $31.73M | $33.97M | $46.33M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $34.63M | $35.98M | $48.94M |
| YoY Change | -23.57% | -26.48% | -28.38% |
Cashflow Statement
| Concept | 2017 Q3 | 2017 Q2 | 2016 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.178M | -$3.880M | -$4.569M |
| YoY Change | 5.66% | -15.08% | 0.23% |
| Depreciation, Depletion And Amortization | $12.84K | $12.96K | $8.762K |
| YoY Change | 35.4% | 47.88% | -2.37% |
| Cash From Operating Activities | -$2.630M | -$3.200M | -$4.340M |
| YoY Change | -19.82% | -26.27% | 2.12% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | -$90.00K |
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$30.00K | $0.00 | $930.0K |
| YoY Change | -101.36% | -100.0% | 2225.0% |
| Cash From Investing Activities | -$30.00K | $0.00 | $840.0K |
| YoY Change | -101.36% | -100.0% | 2700.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.400M | 1.810M | 0.000 |
| YoY Change | -100.0% | ||
| NET CHANGE | |||
| Cash From Operating Activities | -2.630M | -3.200M | -4.340M |
| Cash From Investing Activities | -30.00K | 0.000 | 840.0K |
| Cash From Financing Activities | 1.400M | 1.810M | 0.000 |
| Net Change In Cash | -1.260M | -1.390M | -3.500M |
| YoY Change | 16.67% | -60.29% | -14.63% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.630M | -$3.200M | -$4.340M |
| Capital Expenditures | $0.00 | $0.00 | -$90.00K |
| Free Cash Flow | -$2.630M | -$3.200M | -$4.250M |
| YoY Change | -19.82% | -24.71% | 0.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
84554979 | shares |
| CY2016Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
275007 | |
| CY2017Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
519461 | |
| CY2016Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
18717104 | |
| CY2016Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
122224 | |
| CY2017Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1148080 | |
| CY2017Q2 | us-gaap |
Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
|
1318599 | |
| CY2017Q2 | us-gaap |
Assets Current
AssetsCurrent
|
35752948 | |
| CY2017Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
130234 | |
| CY2017Q2 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
170519 | |
| CY2017Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
139395 | |
| CY2017Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
150879726 | |
| CY2017Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
692345 | |
| CY2017Q2 | us-gaap |
Assets
Assets
|
35980125 | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
8583727 | |
| CY2017Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2017Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
84554979 | shares |
| CY2017Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
2.08 | |
| CY2017Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
84554979 | shares |
| CY2017Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
84555 | |
| CY2017Q2 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
20867 | |
| CY2017Q2 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8888 | |
| CY2017Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
182586 | |
| CY2017Q2 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
26547663 | |
| CY2017Q2 | us-gaap |
Liabilities
Liabilities
|
2010944 | |
| CY2017Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
35980125 | |
| CY2017Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1840425 | |
| CY2017Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2839 | |
| CY2017Q2 | us-gaap |
Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
|
170519 | |
| CY2017Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
33556 | |
| CY2017Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
621558 | |
| CY2017Q2 | us-gaap |
Prepaid Rent
PrepaidRent
|
19906 | |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2017Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2017Q2 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
275563 | |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
218289 | |
| CY2017Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
357684 | |
| CY2017Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-116995100 | |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
3244996 | shares |
| CY2017Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6090000 | shares |
| CY2017Q2 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26547663 | |
| CY2017Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
33969181 | |
| CY2017Q2 | cprx |
Prepaid Research Fee
PrepaidResearchFee
|
218997 | |
| CY2017Q2 | cprx |
Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
|
606554 | |
| CY2017Q2 | cprx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
205000 | |
| CY2017Q2 | cprx |
Prepaid Subscription Fees
PrepaidSubscriptionFees
|
73536 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28235016 | |
| CY2015Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
1008363 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1161359 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
|
1342521 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
41453761 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
102673 | |
| CY2016Q4 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
181162 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
113480 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
147374028 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
933176 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
41706853 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13893064 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
82972316 | shares |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
82972316 | shares |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
82972 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
18094 | |
| CY2016Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8888 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
264237 | |
| CY2016Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
122226 | |
| CY2016Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
26512753 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
2397923 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
41706853 | |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
2094535 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
|
181162 | |
| CY2016Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
36444 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1047944 | |
| CY2016Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
19756 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
598909 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
244204 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
357684 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-108148070 | |
| CY2016Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26512753 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
39308930 | |
| CY2016Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
122226 | |
| CY2016Q4 | cprx |
Prepaid Research Fee
PrepaidResearchFee
|
334565 | |
| CY2016Q4 | cprx |
Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
|
623855 | |
| CY2016Q4 | cprx |
Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
|
35500 | |
| CY2016Q4 | cprx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
152500 | |
| CY2016Q4 | cprx |
Prepaid Subscription Fees
PrepaidSubscriptionFees
|
22770 | |
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6791667 | shares | |
| us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1355290 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
37423 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-5309337 | ||
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
309130 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| us-gaap |
Depreciation
Depreciation
|
25915 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.11 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-06-30 | ||
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
186904 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
CATALYST PHARMACEUTICALS, INC. | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
309130 | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001369568 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
186904 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3595462 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-8847030 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-240831 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-23921 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-426386 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="8%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Organization and Description of Business.</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Catalyst Pharmaceuticals, Inc. (the Company) is a development-stage biopharmaceutical company focused on developing and commercializing innovating therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and infantile spasms.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s primary focus is on the development and commercialization of its drug candidates. The Company has incurred operating losses in each period from inception through June 30, 2017. The Company has been able to fund its cash needs to date through several public and private offerings of its common stock and warrants, through government grants, and through an investment by a strategic purchaser. See Note 9.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Capital Resources</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company may raise required funds through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any such required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business.</p> </div> | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-34910 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-7079864 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
8861142 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1805437 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-8847030 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8861142 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
201016 | ||
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
34910 | ||
| us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
4.64 | ||
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1805437 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5265680 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1392713 | ||
| us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | ||
| cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
1582663 | shares | |
| cprx |
Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
|
Three months | ||
| us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
2114568 | ||
| dei |
Trading Symbol
TradingSymbol
|
CPRX | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
83441650 | shares | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<table style="FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="5%" align="left"><b>b.</b></td> <td valign="top" align="left"><b>USE OF ESTIMATES. </b>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table> | ||
| cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
1582663 | shares | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
815238 | ||
| us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | ||
| us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
4.64 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
82865366 | shares | |
| cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7609330 | shares | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-9517912 | ||
| us-gaap |
Depreciation
Depreciation
|
21960 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.12 | ||
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-886139 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | ||
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
-886139 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4996700 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-9955151 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1086835 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-36572 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-853761 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
767091 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-10273738 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
11051988 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-11265 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-9955151 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11051988 | ||
| us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
210698 | ||
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
11265 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
88929 | ||
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
93263 | ||
| us-gaap |
Proceeds From Payments For In Interest Bearing Deposits In Banks
ProceedsFromPaymentsForInInterestBearingDepositsInBanks
|
949283 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6055288 | ||
| CY2016Q2 | us-gaap |
Depreciation
Depreciation
|
8762 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | |
| CY2016Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-152783 | |
| CY2016Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
| CY2016Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
-152783 | |
| CY2016Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2305555 | |
| CY2016Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-4568914 | |
| CY2016Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2016Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
4814452 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4568914 | |
| CY2016Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4814452 | |
| CY2016Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
92755 | |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2508897 | |
| CY2016Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
357269 | |
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
82870649 | shares |
| CY2016Q2 | cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | shares |
| CY2017Q2 | us-gaap |
Depreciation
Depreciation
|
12957 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
| CY2017Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-210331 | |
| CY2017Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
309130 | |
| CY2017Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
| CY2017Q2 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
|
-210331 | |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1729520 | |
| CY2017Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3879901 | |
| CY2017Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
4181271 | |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3879901 | |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4181271 | |
| CY2017Q2 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
91039 | |
| CY2017Q2 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1805437 | |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2451751 | |
| CY2017Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
638569 | |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
83905827 | shares |
| CY2017Q2 | cprx |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
1582663 | shares |
| CY2017Q2 | cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
1582663 | shares |
